STShingo Takahara

Shingo Takahara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shingo Takahara has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Jason R. B. Dyck

    University of Alberta

    3 shared publications
  • Mourad Ferdaoussi

    Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta , 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2

    3 shared publications
  • Shubham Soni

    Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada

    2 shared publications
  • Zaid H. Maayah

    Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta , 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2

    2 shared publications
  • Anna K. Migglautsch

    Institute of Organic Chemistry, Graz University of Technology, Graz, Austria

    1 shared publication
  • Darren H. Freed

    Department of Surgery, University of Alberta , Edmonton, Alberta

    1 shared publication

Latest Publications

  • Open Access

    Regression of oesophageal varices in total anomalous pulmonary venous connection

    by Shingo Takahara, Naoki Masaki, Hideki Tatewaki, Sadahiro Sai

    The coexisting of oesophageal varices with total anomalous pulmonary venous connection is extremely rare but contains a potential leading to a lethal haemorrhage. The fate of the oesophageal varices after total anomalous pulmonary vein connection repair remains largely unknown. We herein report a case with infracardiac type total anomalous pulmonary venous connection with remarkable oesophageal varices. In the present case, of note, the oesophageal varices were completely regressed after total anomalous pulmonary venous connection repair without any intervention. This case might help a surgical team reduce the hesitation to repair the total anomalous pulmonary venous connection regardless of oesophageal varices, a potentially fatal condition.

  • Open Access

    Chronic Exogenous Ketone Supplementation Blunts the Decline of Cardiac Function in the Failing Heart

    by Shingo Takahara, Shubham Soni, Kiran Phaterpekar, Ty T. Kim, Zaid H. Maayah, Jody L. Levasseur, Heidi L. Silver, Darren H. Freed, Mourad Ferdaoussi, Jason R.B. Dyck

    Aims Recent evidence has demonstrated that ketone bodies, particularly β-hydroxybutyrate (BHB), are beneficial to the failing heart due to their potential as an alternative energy substrate as well as their anti-inflammatory and anti-oxidative properties. Exogenous supplementation of ketones also helps prevent heart failure (HF) development in rodent models, but whether ketones can be used to treat HF remains unexplored. Herein, we investigated whether chronic supplementation of ketones is beneficial for the heart in a mouse model of established HF. Methods and results To elevate circulating ketone levels, we utilized (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate [ketone ester (KE)]. C57Bl/6N male mice were subjected to transverse aortic constriction (TAC) surgery. After developing HF, mice were treated with either 20% KE or vehicle via drinking water for 2 weeks. In another cohort, mice 3–4 weeks post-TAC received acute intravenous infusions of BHB or saline for 1 h and their cardiac function was measured. 20% KE significantly elevated blood BHB in mice (P < 0.01) without inducing ketoacidosis or altering other metabolic parameters. Mice with overt HF (30–45% ejection fraction) treated with 20% KE displayed significantly elevated circulating ketone levels compared with vehicle-treated mice (P < 0.05). The significant cardiac dysfunction in mice with HF continued to worsen after 2 weeks of vehicle treatment, whereas this decline was absent in KE-treated mice (mean difference 4.7% ejection fraction; P < 0.01). KE treatment also alleviated TAC-induced cardiomyocyte hypertrophy (P < 0.05) and reduced the TAC-induced elevated cardiac periostin (P < 0.05), a marker of activated fibroblasts. Cardiac fibrosis was also significantly reduced with KE treatment in TAC mice (P < 0.01). In another cohort, acute BHB infusion significantly increased the cardiac output of mice with HF (P < 0.05), providing further support that ketone therapy can be used to treat HF. Conclusions We show that chronic treatment of exogenous ketones is of benefit to the failing heart and that chronic ketone elevation may be a therapeutic option for HF. Further investigations to elucidate the underlying mechanism(s) are warranted.


  • Ketone therapy for heart failure: current evidence for clinical use

    by Shingo Takahara, Shubham Soni, Zaid H Maayah, Mourad Ferdaoussi, Jason R B Dyck

    During conditions that result in depleted circulating glucose levels, ketone bodies synthesized in the liver are necessary fuel substrates for the brain. In other organs, such as the heart, the reliance on ketones for generating energy in the absence of glucose is less important as the heart can utilize alternative fuel sources, such as fatty acids. However, during pathophysiological conditions, such as heart failure, cardiac defects in metabolic processes that normally allow for sufficient energy production from fatty acids and carbohydrates contribute to a decline in contractile function. As such, it has been proposed that the failing heart relies more on ketone bodies as an energy source than previously appreciated. Furthermore, it has been shown that ketone bodies function as signaling molecules that can suppress systemic and cardiac inflammation. Thus, it is possible that intentionally elevating circulating ketones may be beneficial as an adjunct treatment for heart failure. Although many approaches can be used for ‘ketone therapy’, each of these has their own advantages and disadvantages in the treatment of heart failure. Thus, we summarize current preclinical and clinical studies involving various types of ketone therapy in cardiac disease and discuss the advantages and disadvantages of each modality as possible treatments for heart failure.


  • Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation

    by Shingo Takahara, Mourad Ferdaoussi, Nikola Srnic, Zaid H. Maayah, Shubham Soni, Anna K. Migglautsch, Rolf Breinbauer, Erin E. Kershaw, Jason R. B. Dyck

    The reduction of lipolysis by adipocyte ATGL inhibition ameliorates cardiac remodeling induced by chronic β-adrenergic stimulation likely via reducing galectin-3 secretion from adipose tissue. Our findings highlight that suppressing lipolysis in adipocytes may be a potential therapeutic target for patients with heart failure whose sympathetic nervous system is activated. Furthermore, galectin-3 might be involved in the mechanisms by which excessive lipolysis in adipose tissues influences remote cardiac pathologies and thus warrants further investigation.


  • Open Access

    Modification of a Standard Thoracoabdominal Incision to Preserve Collaterals to Adamkiewicz Artery

    by Shingo Takahara, Keisuke Kanda, Satoshi Kawatsu, Ichiro Yoshioka, Hidenori Fujiwara, Osamu Adachi, Masatoshi Akiyama, Kiichiro Kumagai, Shunsuke Kawamoto, Hideki Ota, et al.